Kyle Diamantas currently serves as acting FDA commissioner following Marty Makary’s May 2026 resignation, placing him at the center of trader attention while the White House continues vetting candidates for a permanent Senate-confirmed role. The near-even split between Diamantas at 28 percent and no announcement by December 31 at 27.9 percent reflects ongoing internal deliberations, the need for background checks and clearance processes, and historical delays in filling subcabinet health positions. Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham remain in consideration at lower odds, but reports of some candidates declining interest and the requirement for Senate confirmation have sustained uncertainty. Any formal nomination, withdrawal of a leading name, or clear signals on timing could quickly shift these probabilities before year-end.